LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Royalty Pharma PLC (Class A)

Gesloten

SectorGezondheidszorg

32.19 -1.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.17

Max

33.05

Belangrijke statistieken

By Trading Economics

Inkomsten

99M

433M

Verkoop

-26M

568M

K/W

Sectorgemiddelde

17.461

56.602

EPS

1.057

Dividendrendement

2.67

Winstmarge

76.275

EBITDA

172M

534M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+17.69% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.67%

2.45%

Volgende Winsten

7 aug 2025

Volgende dividenddatum

10 jun 2025

Volgende Ex Dividend datum

16 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

201M

19B

Vorige openingsprijs

33.99

Vorige sluitingsprijs

32.19

Nieuwssentiment

By Acuity

50%

50%

187 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Royalty Pharma PLC (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2025, 23:40 UTC

Populaire aandelen

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mei 2025, 23:33 UTC

Belangrijke Marktbewegers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mei 2025, 23:25 UTC

Belangrijke Marktbewegers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mei 2025, 23:25 UTC

Winsten

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mei 2025, 22:58 UTC

Winsten

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mei 2025, 21:35 UTC

Winsten

Cisco Systems Names Patterson as CFO, Patel as President

14 mei 2025, 23:59 UTC

Marktinformatie

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mei 2025, 23:49 UTC

Marktinformatie

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mei 2025, 23:48 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2025, 23:48 UTC

Marktinformatie

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mei 2025, 23:47 UTC

Marktinformatie

Gold Gains on Possible Technical Recovery -- Market Talk

14 mei 2025, 23:34 UTC

Acquisities, Fusies, Overnames

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mei 2025, 23:10 UTC

Winsten

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mei 2025, 23:07 UTC

Winsten

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mei 2025, 23:00 UTC

Top Nieuws

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mei 2025, 22:43 UTC

Winsten

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mei 2025, 22:34 UTC

Winsten

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mei 2025, 22:33 UTC

Winsten

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero Did Not Declare a Dividend>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mei 2025, 22:30 UTC

Winsten

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mei 2025, 22:28 UTC

Winsten

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mei 2025, 22:28 UTC

Winsten

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mei 2025, 22:27 UTC

Winsten

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mei 2025, 22:27 UTC

Winsten

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mei 2025, 22:23 UTC

Top Nieuws

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mei 2025, 22:15 UTC

Winsten

Correction to Cisco Earnings Article -- WSJ

14 mei 2025, 21:48 UTC

Winsten

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mei 2025, 21:37 UTC

Winsten

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Vergelijking

Prijswijziging

Royalty Pharma PLC (Class A) Prognose

Koersdoel

By TipRanks

17.69% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 39.25 USD  17.69%

Hoogste 42 USD

Laagste 33 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Royalty Pharma PLC (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technische score

By Trading Central

33 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

187 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.